TET2 and acute myeloid leukemia: These observations were consistent with the rescue of PB counts seen in Figure 6B. Taken together, TFD-driven aggressive AML responds to a combination therapy that targets the mutated receptor tyrosine kinase, epigenetic changes due to Tet2 and Dnmt3a mutations, and inflammation caused by the presence of genetic and epigenetic mutations.